Philip L. Molyneaux
A5062525504- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Medical Imaging and Pathology Studies
- Sarcoidosis and Beryllium Toxicity Research
- Pulmonary Hypertension Research and Treatments
- Inhalation and Respiratory Drug Delivery
- Systemic Sclerosis and Related Diseases
- Respiratory and Cough-Related Research
- Occupational and environmental lung diseases
- Pediatric health and respiratory diseases
- Long-Term Effects of COVID-19
- Respiratory viral infections research
- COVID-19 Clinical Research Studies
- Occupational exposure and asthma
- Pneumonia and Respiratory Infections
- Lung Cancer Diagnosis and Treatment
- Gut microbiota and health
- Inflammatory Myopathies and Dermatomyositis
- Eosinophilic Disorders and Syndromes
- Lung Cancer Treatments and Mutations
- Mycobacterium research and diagnosis
- Neonatal Respiratory Health Research
- Respiratory Support and Mechanisms
- Pleural and Pulmonary Diseases
- Hepatitis C virus research
Imperial College London
2016-2025
Royal Brompton Hospital
2015-2024
Lung Institute
2012-2024
National Institute for Health Research
2014-2024
Guy's and St Thomas' NHS Foundation Trust
2021-2024
Harefield Hospital
2020-2024
National Institutes of Health
2014-2024
NIHR Imperial Biomedical Research Centre
2020-2024
University of Ulster
2021-2024
Royal Victoria Hospital
2021-2024
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown cause that leads to respiratory failure and death within 5 years diagnosis. Overt infection immunosuppression carry high morbidity mortality, polymorphisms in genes related epithelial integrity host defense predispose IPF.To investigate the role bacteria pathogenesis progression IPF.We prospectively enrolled patients diagnosed with IPF according international criteria together healthy smokers, nonsmokers, subjects...
Rationale: The natural history of recovery from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains unknown. Because fibrosis with persistent physiological deficit is a previously described feature patients recovering similar coronaviruses, treatment represents an early opportunity to modify the disease course, potentially preventing irreversible impairment.Objectives: Determine incidence and describe progression inflammatory interstitial lung (ILD) following SARS-CoV-2 when...
Rhinovirus infection is followed by significantly increased frequencies of positive, potentially pathogenic sputum cultures in chronic obstructive pulmonary disease (COPD). However, it remains unclear whether these represent de novo infections or an load organisms from the complex microbial communities (microbiome) lower airways.To investigate effect rhinovirus on airway bacterial microbiome.Subjects with COPD (n = 14) and healthy control subjects normal lung function 17) were infected...
Pulmonary fibrosis is a progressive inflammatory disease with high mortality and limited therapeutic options. Previous genetic immunologic investigations suggest common intersections between idiopathic pulmonary (IPF), sarcoidosis, murine models of fibrosis. To identify immune responses that precede collagen deposition, we conducted molecular, immunohistochemical, flow cytometric analysis human specimens. Immunohistochemistry revealed programmed cell death-1 (PD-1) up-regulation on IPF...
BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high mortality, uncertain cause, and few treatment options. Studies have identified significant genetic risk associated the development of IPF; however, mechanisms by which factors promote IPF remain unclear. We aimed to identify variants susceptibility provide mechanistic insight using gene protein expression analyses.MethodsWe used two-stage approach: genome-wide association study in patients European...
Rationale: Idiopathic pulmonary fibrosis (IPF) is a complex lung disease characterized by scarring of the that believed to result from an atypical response injury epithelium. Genome-wide association studies have reported signals implicating multiple pathways including host defense, telomere maintenance, signaling, and cell-cell adhesion.Objectives: To improve our understanding factors increase IPF susceptibility identifying previously unreported genetic associations.Methods: We conducted...
<h3>Background</h3> A polymorphism (rs35705950) 3 kb upstream of <i>MUC5B</i>, the gene encoding Mucin 5 subtype B, has been shown to be associated with familial and sporadic idiopathic pulmonary fibrosis (IPF). We set out verify whether this variant is also a risk factor for fibrotic lung disease in other settings confirm published findings UK Caucasian IPF population. <h3>Methods</h3> healthy controls (n=416) patients (n=110), sarcoidosis (n=180) systemic sclerosis (SSc) (n=440) were...
The impact of coronavirus disease (COVID-19) on patients with interstitial lung (ILD) has not been established.
Changes in the respiratory microbiome are associated with disease progression idiopathic pulmonary fibrosis (IPF). The role of host response to remains unknown.To explore host-microbial interactions IPF.Sixty patients diagnosed IPF were prospectively enrolled together 20 matched control subjects. Subjects underwent bronchoalveolar lavage (BAL), and peripheral whole blood was collected into PAXgene tubes for all subjects at baseline. For IPF, additional samples taken 1, 3, 6 months (if alive)...
Galectin (Gal)-3 is a profibrotic β-galactoside-binding lectin that plays key role in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and IPF exacerbations. TD139 novel potent small-molecule inhibitor Gal-3. A randomised, double-blind, multicentre, placebo-controlled, phase 1/2a study was conducted to assess safety, tolerability, pharmacokinetics pharmacodynamics inhaled 36 healthy subjects 24 patients with IPF. Six dose cohorts six were evaluated (4:2 TD139:placebo ratio) single...
Rituximab is often used as rescue therapy in interstitial lung disease (ILD) associated with connective tissue (CTD), but has not been studied clinical trials. This study aimed to assess whether rituximab superior cyclophosphamide a treatment for severe or progressive CTD ILD.
Rationale: There is an urgent need for simple, cost-effective prognostic biomarkers idiopathic pulmonary fibrosis (IPF); that show potential include monocyte count. Objectives: We used pooled data from pirfenidone and IFNγ-1b trials to explore the association between count prognosis in patients with IPF. Methods: This retrospective analysis included (active placebo arms) following four phase III, randomized, placebo-controlled trials: ASCEND (NCT01366209), CAPACITY (NCT00287729 NCT00287716),...
Some patients hospitalized with acute COVID-19 suffer respiratory symptoms that persist for many months. We delineated the immune-proteomic landscape in airways and peripheral blood of healthy controls post-COVID-19 3 to 6 months after hospital discharge. Post-COVID-19 showed abnormal airway (but not plasma) proteomes, an elevated concentration proteins associated apoptosis, tissue repair, epithelial injury versus individuals. Increased numbers cytotoxic lymphocytes were observed individuals...
Rationale: Shared symptoms and genetic architecture between coronavirus disease (COVID-19) lung fibrosis suggest severe acute respiratory syndrome 2 (SARS-CoV-2) infection may lead to progressive damage. Objectives: The UK Interstitial Lung Disease Consortium (UKILD) post–COVID-19 study interim analysis was planned estimate the prevalence of residual abnormalities in people hospitalized with COVID-19 on basis risk strata. Methods: PHOSP–COVID-19 (Post-Hospitalization COVID-19) used capture...
Rationale: Criteria for progressive pulmonary fibrosis (PPF) have been proposed, but their prognostic value beyond categorical decline in FVC remains unclear. Objectives: To determine whether proposed PPF criteria predict transplant-free survival (TFS) patients with non–idiopathic (IPF) forms of interstitial lung disease (ILD). Methods: A retrospective, multicenter cohort analysis was performed. Patients diagnoses fibrotic connective tissue disease–associated ILD, hypersensitivity...
There is a major need for effective, well-tolerated treatments idiopathic pulmonary fibrosis (IPF).To assess the efficacy and safety of autotaxin inhibitor ziritaxestat in patients with IPF.The 2 identically designed, phase 3, randomized clinical trials, ISABELA 1 2, were conducted Africa, Asia-Pacific region, Europe, Latin America, Middle East, North America (26 countries). A total 1306 IPF (525 at 106 sites 781 121 2). Enrollment began November 2018 both trials follow-up was completed...